Nuvectis Pharma, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage oncology drug developer with common stock registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and annual financial results, corporate updates, and exhibit press releases describing development activity for NXP900 and related operating progress.
Proxy materials cover annual meeting matters, director elections, auditor ratification, board composition, and stockholder voting procedures. Other material-event filings record governance changes such as director appointments, while cover-page disclosures identify Nuvectis as an emerging growth company and list its common stock trading on the Nasdaq Capital Market under NVCT.
Nuvectis Pharma reported first-quarter 2026 results, continuing as a clinical-stage oncology company with no product revenue. Net loss was $6.1 million, compared with $5.3 million a year earlier, driven by higher research and development and public-company costs.
Research and development expenses were $4.1 million and general and administrative expenses were $2.2 million. Cash and cash equivalents totaled $25.1 million at March 31 2026, which management believes can fund operations for at least 12 months.
The accumulated deficit reached $105.7 million. Shares outstanding rose to 26,525,533, reflecting equity-based compensation and modest use of the at-the-market program, which still has $60.0 million capacity within a broader $150.0 million shelf registration. Lead asset NXP900 remains in Phase 1b development.
Nuvectis Pharma reported first quarter 2026 results and highlighted progress in its NXP900 oncology program. Cash and cash equivalents were $25.1 million as of March 31, 2026, down from $31.6 million as of December 31, 2025, reflecting ongoing development spending.
The company recorded a net loss of $6.1 million for the quarter, compared with $5.3 million a year earlier, as research and development expenses rose to $4.1 million and general and administrative expenses to $2.2 million. Net loss per share was $0.26 based on 23.4 million weighted average shares outstanding.
Nuvectis is advancing NXP900, an oral small molecule SRC Family Kinase inhibitor, in an ongoing Phase 1b study, with a preliminary data readout expected in the summer of 2026. Preclinical data presented at AACR showed synergistic activity when NXP900 was combined with sotorasib in non-small cell lung cancer models.
Nuvectis Pharma, Inc. is holding a virtual Annual Meeting of Stockholders on June 11, 2026 at 10:00 a.m. Eastern Time via www.virtualshareholdermeeting.com/NVCT2026. Stockholders of record as of April 13, 2026, when 27,668,036 common shares were outstanding, are entitled to vote.
Stockholders will vote on electing co‑founder and CEO Ron Bentsur as a Class I director for a new three‑year term and on ratifying Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the year ending December 31, 2026.
The proxy details board structure, committee memberships, and independence determinations, and outlines executive and director pay, including significant restricted stock awards and change‑of‑control protections. Directors, executive officers, and 5% beneficial owners collectively control about 39.89% of the company’s common stock.
Nuvectis Pharma has filed a shelf registration statement on Form S-3 allowing it to offer up to $150,000,000 of common stock, preferred stock, warrants, debt securities and units over time. This structure lets the company raise capital in multiple transactions using a single overarching prospectus.
The filing includes a dedicated at-the-market program to sell up to $60,000,000 of common stock through Leerink Partners, with $45,580,233.34 of capacity carried over from a prior sales agreement prospectus. Nuvectis, an emerging growth oncology company, plans to use proceeds primarily to advance its NXP900 clinical program and other corporate needs, while retaining flexibility to issue different types of securities as market conditions and development plans evolve.
Nuvectis Pharma, Inc. reported wider losses for 2025 as it advanced its lead oncology candidate NXP900 through early-stage clinical development. Cash and cash equivalents were $31.6 million as of December 31, 2025, up from $18.5 million a year earlier, mainly from a February 2025 public offering and use of its at-the-market facility.
The company’s net loss was $26.4 million for 2025 compared with $19.0 million in 2024, driven by higher research and development and general and administrative expenses, including $6.0 million of non-cash stock-based compensation and $2.4 million of one-time license milestone fees. Research and development expenses rose to $18.2 million, while general and administrative costs increased to $9.4 million.
Management highlighted progress in the NXP900 program, including an ongoing Phase 1b monotherapy study across selected tumor types and a combination study with osimertinib in EGFR-mutated NSCLC, with a lorlatinib combination in ALK-positive NSCLC pending initiation. The company believes its current cash can fund multiple NXP900 Phase 1b milestones and operations well into the second half of 2027.
Nuvectis Pharma, Inc. files its annual report, outlining a clinical-stage oncology business focused on precision medicines. The lead candidate, NXP900, is an oral SRC/YES1 kinase inhibitor licensed from the University of Edinburgh, with Phase 1a completed and a Phase 1b expansion under way in solid tumors.
The company has ceased clinical development of its other candidate, NXP800, after a Phase 1b study and is assessing possible next steps. As of December 31, 2025, accumulated losses reached $99.7 million, and the company expects continued losses as it advances development, relies on third-party manufacturers, and operates in a heavily regulated and competitive biopharmaceutical environment.
Nuvectis Pharma, Inc. reported that Chief Dev. & Ops. Officer Shay Shemesh received an award of 150,000 shares of restricted common stock on 01/06/2026 at a price of $0 per share.
The restricted shares will vest in equal annual installments over three years beginning on the first anniversary of the grant date, subject to his continued service. After this grant, Shemesh beneficially owns 1,793,068 shares of Nuvectis common stock, including restricted shares, held directly.
Nuvectis Pharma, Inc. reported an equity award to its Chairman and CEO, Ron Bentsur. On 01/06/2026, he was granted 150,000 shares of restricted common stock at a price of $0 per share. These restricted shares will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues to serve with the company on each vesting date.
After this grant, Mr. Bentsur beneficially owns 3,675,924 shares of Nuvectis Pharma common stock, held directly, which includes previously granted restricted shares.
Nuvectis Pharma, Inc. reported an equity grant to a senior officer. Chief Science & Business Officer Enrique Poradosu received 150,000 shares of restricted common stock on January 6, 2026, at a stated price of $0 per share, reflecting a compensatory award rather than an open-market purchase.
The 150,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Poradosu’s continued service on each vesting date. Following this grant, he beneficially owned 1,806,319 shares of Nuvectis common stock, which includes restricted shares.